Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system
JA Lewnard, JM McLaughlin, D Malden, V Hong… - medRxiv, 2022 - medrxiv.org
ABSTRACT Background In the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …
Effectiveness of nirmatrelvir-ritonavir against hospital admission: a matched cohort study in a large US healthcare system.
JA Lewnard, D Malden, V Hong, L Puzniak… - Medrxiv: the Preprint …, 2022 - europepmc.org
In the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is authorized for use among
patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 infection who are at risk for …
patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 infection who are at risk for …
[PDF][PDF] Effectiveness of nirmatrelvir-ritonavir against hospital admission: a matched cohort study in a large US healthcare system
JA Lewnard, S Kim - researchgate.net
ABSTRACT Background: In the United States, oral nirmatrelvir-ritonavir (PaxlovidTM) is
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …
Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system
JA Lewnard, JM McLaughlin… - … : the preprint server …, 2023 - pubmed.ncbi.nlm.nih.gov
Background In the United States, oral nirmatrelvir-ritonavir (PaxlovidTM) is authorized for
use among patients aged 12+ years with mild-to-moderate SARS-CoV-2 infection who are at …
use among patients aged 12+ years with mild-to-moderate SARS-CoV-2 infection who are at …
Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system
JA Lewnard, JM McLaughlin, D Malden, V Hong… - medRxiv - ncbi.nlm.nih.gov
Background: In the United States, oral nirmatrelvir-ritonavir (PaxlovidTM) is authorized for
use among patients aged 12+ years with mild-to-moderate SARS-CoV-2 infection who are at …
use among patients aged 12+ years with mild-to-moderate SARS-CoV-2 infection who are at …
Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system
JA Lewnard, JM McLaughlin, D Malden, V Hong… - 2022 - europepmc.org
Background In the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is authorized for use
among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 infection who are at …
among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 infection who are at …